Table 1 Demographic and clinical characteristics of the patients at baseline
Characteristic | Remimazolam (n = 30) | Propofol (n = 30) | p value |
|---|---|---|---|
Age, years | 62.0 (52.0, 69.5) | 64.5 (57.8, 69.3) | 0.525 |
Male | 21 (70.0%) | 20 (66.7%) | 0.781 |
BMI, kg/m2 | 23.1 ± 2.9 | 24.1 ± 3.1 | 0.222 |
APACHE II score | 16.0 (13.8, 18.0) | 16.0 (12.0, 17.3) | 0.947 |
SOFA score | 7.0 (4.0, 8.0) | 7.5 (5.0, 9.0) | 0.146 |
RASS score | − 5.0 (− 5.0, − 4.0) | − 5.0 (− 5.0, − 5.0) | 0.139 |
Narcotrend index | 34.3 (9.7) | 29.7 (9.3) | 0.067 |
Duration of MV before randomization, h | 23.5 (14.0, 52.3) | 23.0 (13.0, 46.3) | 0.970 |
Type of admission | |||
Medical | 14 (46.7%) | 12 (40.0%) | |
Surgical | 13 (43.3%) | 13 (43.3%) | |
Trauma | 3 (10.0%) | 5 (16.7) | |
Reasons for deep sedation | |||
ARDS | 24 (80.0%) | 21 (70.0%) | |
Sepsis | 1 (3.3%) | 7 (23.3%) | |
Multiple rib fractures | 1 (3.3%) | 1 (3.3%) | |
Hemorrhagic shock | 1 (3.3%) | 1 (3.3%) | |
Patient-ventilator asynchrony | 2 (6.7%) | 0 (0.0%) | |
Heart failure | 1 (3.3%) | 0 (0.0%) | |
Comorbidities | |||
Hypertension | 11 (36.7%) | 13 (43.3%) | 0.598 |
Coronary artery disease | 6 (20.0%) | 5 (16.7%) | 0.739 |
COPD | 3 (10.0%) | 0 (0.0%) | 0.237 |
Diabetes | 7 (23.3%) | 4 (13.3%) | 0.317 |
Cancer | 5 (16.7%) | 6 (20.0%) | 0.739 |
Pre-study sedative | |||
Remimazolam | 12 (40.0%) | 9 (30.0%) | 0.417 |
Propofol | 5 (16.7%) | 6 (20.0%) | 0.739 |
Midazolam | 18 (60.0%) | 19 (63.3%) | 0.791 |
Dexmedetomidine | 2 (6.7%) | 2 (6.7%) | 1.000 |
Organ dysfunction | |||
PaO2/FiO2 ratio, mmHg | 192.5 (147.5, 279.8) | 196.5 (119.5, 238.0) | 0.657 |
Vasopressors | 15 (50.0%) | 20 (66.7%) | 0.190 |
Platelets, 109/L | 146.5 (93.0, 236.8) | 136.0 (80.0, 184.3) | 0.367 |
Bilirubin, μmol/L | 15.6 (11.3, 29.7) | 20.0 (17.2, 33.4) | 0.246 |
Creatinine, μmol/L | 88.9 (61.1, 122.3) | 97.1 (62.6, 148.3) | 0.455 |